Key terms

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MNKD news

Apr 08 10:30pm ET Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO) by TipRanks Apr 03 4:06pm ET MannKind management to meet with Oppenheimer by TipRanks Apr 03 6:12am ET MannKind repays certain debt obligations by TipRanks Mar 26 4:23pm ET MannKind Corp Announces CFO Transition and New Compensation Plan by TipRanks Mar 26 4:20pm ET MannKind CFO Binder to retire, Christopher Prentiss named successor by TipRanks Mar 11 6:09am ET MannKind announces initial meal challenge data from INHALE-3 study by TipRanks Mar 05 10:25am ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Mar 05 4:55am ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Mar 01 12:19pm ET Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call by TipRanks Mar 01 1:06am ET MannKind’s Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating by TipRanks Feb 28 8:55am ET MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating by TipRanks Feb 28 8:35am ET MannKind (MNKD) Receives a New Rating from Cantor Fitzgerald by TipRanks Feb 28 7:19am ET RBC Capital Sticks to Their Hold Rating for MannKind (MNKD) by TipRanks Feb 27 4:04pm ET MannKind reports Q4 EPS 0c, consensus 0c by TipRanks Feb 27 3:19pm ET MannKind options imply 10.8% move in share price post-earnings by TipRanks Feb 15 6:17am ET MannKind says INHALE-1 study now fully enrolled by TipRanks

No recent press releases are available for MNKD

MNKD Financials

1-year income & revenue

Key terms

MNKD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MNKD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching
Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments